Needham & Company LLC Has Lowered Expectations for Phreesia (NYSE:PHR) Stock Price

Phreesia (NYSE:PHR) had its target price decreased by stock analysts at Needham & Company LLC from $35.00 to $14.00 in a research note issued on Tuesday, MarketBeat reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price target indicates a potential upside of 66.69% from the company’s previous close.

A number of other brokerages have also weighed in on PHR. Citigroup dropped their price objective on Phreesia from $29.00 to $25.00 and set a “buy” rating on the stock in a report on Friday, January 9th. Wall Street Zen lowered shares of Phreesia from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 8th. Truist Financial set a $24.00 price target on shares of Phreesia in a research note on Thursday, January 8th. DA Davidson cut their price target on shares of Phreesia from $35.00 to $30.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Finally, Royal Bank Of Canada initiated coverage on shares of Phreesia in a research note on Friday, January 9th. They issued a “moderate buy” rating and a $26.00 price objective for the company. Twelve analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Phreesia presently has an average rating of “Moderate Buy” and an average price target of $22.00.

Phreesia Stock Up 0.2%

PHR stock opened at $8.40 on Tuesday. The company has a market cap of $506.35 million, a price-to-earnings ratio of 279.97 and a beta of 0.67. The company has a fifty day moving average price of $12.21 and a 200 day moving average price of $17.51. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.44 and a quick ratio of 2.44. Phreesia has a 12 month low of $7.77 and a 12 month high of $32.76.

Phreesia (NYSE:PHR) last posted its quarterly earnings data on Monday, March 30th. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.05). Phreesia had a net margin of 0.48% and a return on equity of 3.33%. The business had revenue of $127.07 million during the quarter, compared to analyst estimates of $126.75 million. During the same quarter in the prior year, the firm posted ($0.11) earnings per share. The company’s revenue for the quarter was up 15.9% compared to the same quarter last year. Sell-side analysts expect that Phreesia will post -1.1 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Balaji Gandhi sold 3,829 shares of the stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $11.26, for a total value of $43,114.54. Following the sale, the chief financial officer directly owned 146,740 shares of the company’s stock, valued at approximately $1,652,292.40. This represents a 2.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Allison C. Hoffman sold 6,176 shares of the firm’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $11.97, for a total transaction of $73,926.72. Following the transaction, the general counsel owned 163,485 shares of the company’s stock, valued at $1,956,915.45. This trade represents a 3.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 70,358 shares of company stock worth $1,123,569. 5.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Hsbc Holdings PLC raised its position in shares of Phreesia by 96.2% during the 4th quarter. Hsbc Holdings PLC now owns 46,558 shares of the company’s stock worth $786,000 after purchasing an additional 22,829 shares during the last quarter. Rockefeller Capital Management L.P. lifted its position in shares of Phreesia by 354.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 2,755 shares of the company’s stock valued at $47,000 after acquiring an additional 2,149 shares in the last quarter. Alpine Global Management LLC acquired a new stake in shares of Phreesia during the fourth quarter valued at $179,000. Invesco Ltd. boosted its stake in shares of Phreesia by 13.1% during the fourth quarter. Invesco Ltd. now owns 82,176 shares of the company’s stock valued at $1,390,000 after acquiring an additional 9,514 shares during the last quarter. Finally, State of Tennessee Department of Treasury purchased a new stake in Phreesia during the 4th quarter worth about $202,000. 92.10% of the stock is owned by hedge funds and other institutional investors.

Phreesia News Roundup

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Q4 operating results showed revenue growth and much stronger free cash flow, giving a fundamental floor under the shares; transcripts and presentations highlight record revenue growth and improving FCF. Earnings Presentation
• Positive Sentiment: Stephens lowered its price target but kept an “overweight” stance (new PT $20), signaling some analysts still see sizable upside from current levels despite weaker guidance. Stephens Coverage
• Neutral Sentiment: Multiple firms reiterated neutral/hold or market‑perform ratings (JPMorgan, Robert W. Baird, Citigroup, Truist, Citizens Jmp) while trimming price targets — this keeps the stock in analysts’ coverage but signals cautious sentiment. Analyst Radar
• Negative Sentiment: Management cut FY2027 revenue guidance to $510M–$520M (from $545M–$559M), citing reduced visibility into pharma client spending and weaker H2 commitments — the guidance cut is the primary driver of recent heavy selling. Guidance Coverage
• Negative Sentiment: Shares plunged after the outlook cut and several firms lowered price targets (examples: Needham, BMO, Canaccord lowered targets; multiple downgrades and PT trims followed the guidance update), increasing near-term downside risk. Downgrades Coverage
• Negative Sentiment: Levi & Korsinsky has opened an investigation into potential securities-law violations related to Phreesia, introducing legal/uncertainty risk that can amplify volatility and weighing on sentiment. Investigation Notice
• Negative Sentiment: Some sell-side commentary withdrew buy recommendations or explicitly flagged disappointment with the growth outlook, which can pressure flows and limit short‑term buyers. Analyst Reaction

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.